Aristotle Capital Boston LLC Sells 60,448 Shares of Guardian Pharmacy Services, Inc. $GRDN

Aristotle Capital Boston LLC decreased its position in Guardian Pharmacy Services, Inc. (NYSE:GRDN) by 9.3% during the fourth quarter, HoldingsChannel reports. The firm owned 589,015 shares of the company’s stock after selling 60,448 shares during the quarter. Aristotle Capital Boston LLC’s holdings in Guardian Pharmacy Services were worth $17,723,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Ameritas Investment Partners Inc. increased its position in Guardian Pharmacy Services by 26.5% during the third quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company’s stock worth $43,000 after acquiring an additional 345 shares during the period. California State Teachers Retirement System grew its position in Guardian Pharmacy Services by 3.4% in the 4th quarter. California State Teachers Retirement System now owns 17,983 shares of the company’s stock worth $541,000 after purchasing an additional 593 shares during the last quarter. Police & Firemen s Retirement System of New Jersey grew its position in Guardian Pharmacy Services by 20.4% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 6,070 shares of the company’s stock worth $183,000 after purchasing an additional 1,028 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Guardian Pharmacy Services by 13.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 11,885 shares of the company’s stock worth $358,000 after purchasing an additional 1,409 shares during the period. Finally, Clearstead Advisors LLC increased its holdings in shares of Guardian Pharmacy Services by 196.3% during the 4th quarter. Clearstead Advisors LLC now owns 2,628 shares of the company’s stock worth $79,000 after purchasing an additional 1,741 shares during the period.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Guardian Pharmacy Services in a research note on Monday, March 30th. They issued a “buy” rating and a $44.00 target price for the company. Truist Financial increased their target price on shares of Guardian Pharmacy Services from $43.00 to $47.00 and gave the company a “buy” rating in a research note on Wednesday. Weiss Ratings cut shares of Guardian Pharmacy Services from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Wall Street Zen cut shares of Guardian Pharmacy Services from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Bank of America increased their target price on shares of Guardian Pharmacy Services from $42.00 to $47.00 and gave the company a “buy” rating in a research note on Wednesday. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $42.83.

Insider Activity

In other Guardian Pharmacy Services news, Director John Ackerman sold 1,103,364 shares of the business’s stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $29.68, for a total transaction of $32,747,843.52. Following the completion of the sale, the director directly owned 345,123 shares of the company’s stock, valued at approximately $10,243,250.64. The trade was a 76.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider David K. Morris sold 187,855 shares of the business’s stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $29.68, for a total value of $5,575,536.40. Following the sale, the insider directly owned 254,472 shares of the company’s stock, valued at $7,552,728.96. This represents a 42.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 9,726,405 shares of company stock worth $288,679,700. Corporate insiders own 32.96% of the company’s stock.

Guardian Pharmacy Services Stock Performance

Shares of NYSE:GRDN opened at $43.43 on Thursday. Guardian Pharmacy Services, Inc. has a 52 week low of $19.30 and a 52 week high of $43.96. The company’s fifty day moving average is $38.52 and its 200-day moving average is $34.41. The company has a market capitalization of $2.16 billion, a PE ratio of 52.32, a P/E/G ratio of 2.78 and a beta of 0.08.

Guardian Pharmacy Services (NYSE:GRDN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.05. The business had revenue of $336.60 million for the quarter, compared to the consensus estimate of $329.89 million. Guardian Pharmacy Services had a net margin of 3.64% and a return on equity of 30.72%. The firm’s quarterly revenue was up 2.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.22 EPS. On average, analysts forecast that Guardian Pharmacy Services, Inc. will post 1.18 EPS for the current year.

Guardian Pharmacy Services Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.